Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
This trial is active, not recruiting.
|Treatments||incomplete freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim|
|Sponsor||University of Virginia|
|Collaborator||National Cancer Institute (NCI)|
|Start date||September 2003|
|Trial identifier||NCT00089193, CDR0000378169, FCCC-03045, MDA-2003-0720, UVACC-28903, UVACC-HIC-10524, UVACC-MEL-43|
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells.
PURPOSE: This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients with stage II B, stage IIC, stage III, or stage IV melanoma.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Washington, DC||Washington Cancer Institute at Washington Hospital Center||no longer recruiting|
|Philadelphia, PA||Fox Chase Cancer Center||no longer recruiting|
|Pittsburgh, PA||Hillman Cancer Center at University of Pittsburgh Cancer Institute||no longer recruiting|
|Houston, TX||MD Anderson Cancer Center at University of Texas||no longer recruiting|
|Charlottesville, VA||Cancer Center at the University of Virginia||no longer recruiting|
Male or female participants at least 12 years old.
DISEASE CHARACTERISTICS: - Diagnosis of melanoma - Stage IIB, IIC, III, or IV disease - Must express HLA-A1, -A2, or -A3 - No ocular melanoma PATIENT CHARACTERISTICS: Age - 12 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count > 1,000/mm^3 - Platelet count > 100,000/mm^3 - Hemoglobin > 9 g/dL Hepatic - Liver function tests ≤ 2.5 times upper limit of normal (ULN) Renal - Creatinine ≤ 1.5 times ULN Cardiovascular - No New York Heart Association class III or IV heart disease Other - Not pregnant or nursing - No other malignancy within the past 5 years except basal cell or squamous cell skin cancer without brain metastasis, carcinoma in situ of the breast, or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - More than 4 weeks since prior immunotherapy - More than 4 weeks since prior growth factors - More than 4 weeks since prior allergy shots - No prior vaccine therapy for melanoma or any other cancer with any of the peptides used in this study - More than 12 weeks since prior melanoma vaccine therapy* NOTE: *Prior melanoma vaccine allowed only for patients with disease progression during or after administration of the vaccine Chemotherapy - More than 4 weeks since prior chemotherapy Endocrine therapy - More than 4 weeks since prior steroids Radiotherapy - More than 4 weeks since prior radiotherapy Surgery - Not specified
|Official title||Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides|
|Description||OBJECTIVES: - Compare immune response in patients with stage IIB-IV melanoma treated with vaccination comprising multiple synthetic melanoma peptides and Montanide ISA-51 with vs without sargramostim (GM-CSF). - Compare immune response in patients treated with these vaccinations administered at 1 vs 2 sites. OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 4 treatment arms. - Arm I: Patients receive vaccination comprising multiple synthetic melanoma peptides and Montanide ISA-51 at 1 injection site. - Arm II: Patients receive vaccination comprising multiple synthetic melanoma peptides and Montanide ISA-51 at 2 injection sites. - Arm III: Patients receive vaccination comprising multiple synthetic melanoma peptides, Montanide ISA-51, and sargramostim (GM-CSF) at 1 injection site. - Arm IV: Patients receive vaccination comprising multiple synthetic melanoma peptides, Montanide ISA-51, and GM-CSF at 2 injection sites. In all arms, treatment repeats once weekly for 6 weeks. Patients return for booster vaccinations at weeks 12, 26, 39, and 52. PROJECTED ACCRUAL: A maximum of 124 patients will be accrued for this study.|
Call for more information